Antibodies targeting the SARS-CoV-2 spike receptor-binding domain (RBD) are being developed
as therapeutics and are a major contributor to neutralizing antibody responses elicited …

Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA are frequently observed
in COVID-19. However, it is unclear whether SARS-CoV-2 replicates in the human intestine …

Neutralizing antibodies against the SARS-CoV-2 spike (S) protein are a goal of COVID-19
vaccines and have received emergency use authorization as therapeutics. However, viral …

The SARS-CoV-2 spike (S) glycoprotein contains an immunodominant receptor-binding
domain (RBD) targeted by most neutralizing antibodies (Abs) in COVID-19 patient plasma. Little …

Antibodies are a principal determinant of immunity for most RNA viruses and have promise
to reduce infection or disease during major epidemics. The novel coronavirus SARS-CoV-2 …

The global emergence of many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variants jeopardizes the protective antiviral immunity induced after infection or …

Antibody-based interventions against SARS-CoV-2 could limit morbidity, mortality, and
possibly transmission. An anticipated correlate of such countermeasures is the level of …

Cholesterol 25-hydroxylase (CH25H) is an interferon (IFN)-stimulated gene that shows
broad antiviral activities against a wide range of enveloped viruses. Here, using an IFN-…

Virus entry is a multistep process. It initiates when the virus attaches to the host cell and
ends when the viral contents reach the cytosol. Genetically unrelated viruses can subvert …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) variants govern
transmissibility, responsiveness to vaccination, and disease severity. In a screen for new …